FMP

FMP

Enter

APDN - Applied DNA Sciences...

photo-url-https://images.financialmodelingprep.com/symbol/APDN.png

Applied DNA Sciences, Inc.

APDN

NASDAQ

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

2.26 USD

-0.395 (-17.48%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

1.93M

9.03M

18.17M

13.37M

3.43M

4.28M

5.35M

6.67M

8.33M

10.39M

Revenue %

-

367.4

101.25

-26.43

-74.33

24.81

24.81

24.81

24.81

Ebitda

-12.25M

-11.68M

-12.68M

-9.59M

-14.02M

-3.78M

-4.72M

-5.89M

-7.35M

-9.18M

Ebitda %

-634.19

-129.41

-69.79

-71.75

-408.72

-88.31

-88.31

-88.31

-88.31

Ebit

-12.53M

-12.53M

-13.97M

-10.95M

-14.02M

-3.93M

-4.91M

-6.12M

-7.64M

-9.54M

Ebit %

-648.98

-138.76

-76.89

-81.94

-408.72

-91.77

-91.77

-91.77

-91.77

Depreciation

285.73k

844.44k

1.29M

1.36M

-

354.96k

443.03k

552.95k

690.15k

861.38k

Depreciation %

14.79

9.35

7.1

10.19

-

8.29

8.29

8.29

8.29

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

7.79M

6.55M

15.22M

7.15M

6.43M

3.51M

4.38M

5.47M

6.83M

8.52M

Total Cash %

403.15

72.61

83.74

53.5

187.42

81.97

81.97

81.97

81.97

Receivables

194.32k

2.8M

3.07M

255.5k

362.01k

603.58k

753.34k

940.25k

1.17M

1.46M

Receivables %

10.06

31.06

16.88

1.91

10.55

14.09

14.09

14.09

14.09

Inventories

497.37k

1.37M

602.24k

330.03k

438.59k

509.57k

636k

793.8k

990.75k

1.24M

Inventories %

25.75

15.17

3.31

2.47

12.78

11.9

11.9

11.9

11.9

Payable

1.25M

1.36M

1.74M

1.07M

1.17M

1.12M

1.4M

1.75M

2.19M

2.73M

Payable %

64.72

15.01

9.6

8.02

33.97

26.26

26.26

26.26

26.26

Cap Ex

-1.06M

-2.55M

-489.55k

-78.45k

-407.9k

-843.47k

-1.05M

-1.31M

-1.64M

-2.05M

Cap Ex %

-55.07

-28.23

-2.69

-0.59

-11.89

-19.69

-19.69

-19.69

-19.69

Weighted Average Cost Of Capital

Price

2.26

Beta

Diluted Shares Outstanding

3.97M

Costof Debt

4.09

Tax Rate

After Tax Cost Of Debt

4.03

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

739.16k

Total Equity

8.96M

Total Capital

9.7M

Debt Weighting

7.62

Equity Weighting

92.38

Wacc

5.92

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

1.93M

9.03M

18.17M

13.37M

3.43M

4.28M

5.35M

6.67M

8.33M

10.39M

Ebitda

-12.25M

-11.68M

-12.68M

-9.59M

-14.02M

-3.78M

-4.72M

-5.89M

-7.35M

-9.18M

Ebit

-12.53M

-12.53M

-13.97M

-10.95M

-14.02M

-3.93M

-4.91M

-6.12M

-7.64M

-9.54M

Tax Rate

1.35

1.35

1.35

1.35

1.35

1.35

1.35

1.35

1.35

1.35

Ebiat

-12.28M

-14.06M

-14.15M

-10.87M

-13.84M

-3.9M

-4.86M

-6.07M

-7.58M

-9.46M

Depreciation

285.73k

844.44k

1.29M

1.36M

-

354.96k

443.03k

552.95k

690.15k

861.38k

Receivables

194.32k

2.8M

3.07M

255.5k

362.01k

603.58k

753.34k

940.25k

1.17M

1.46M

Inventories

497.37k

1.37M

602.24k

330.03k

438.59k

509.57k

636k

793.8k

990.75k

1.24M

Payable

1.25M

1.36M

1.74M

1.07M

1.17M

1.12M

1.4M

1.75M

2.19M

2.73M

Cap Ex

-1.06M

-2.55M

-489.55k

-78.45k

-407.9k

-843.47k

-1.05M

-1.31M

-1.64M

-2.05M

Ufcf

-12.5M

-19.14M

-12.46M

-7.17M

-14.36M

-4.74M

-5.47M

-6.83M

-8.52M

-10.64M

Wacc

5.92

5.92

5.92

5.92

5.92

Pv Ufcf

-4.47M

-4.88M

-5.75M

-6.77M

-7.98M

Sum Pv Ufcf

-29.85M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

5.92

Free Cash Flow T1

-10.85M

Terminal Value

-276.59M

Present Terminal Value

-207.43M

Intrinsic Value

Enterprise Value

-237.28M

Net Debt

-5.69M

Equity Value

-231.59M

Diluted Shares Outstanding

3.97M

Equity Value Per Share

-58.39

Projected DCF

-58.39 1.039%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep